AN2 Therapeutics, Inc. (ANTX) NASDAQ
4.00
+0.2(+5.26%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
4.00
+0.2(+5.26%)
Currency In USD
Address
1800 El Camino Real
Menlo Park, CA 94027
United States of America (the)
Phone
650-331-9090
Sector
Healthcare
Industry
Biotechnology
Employees
22
First IPO Date
March 25, 2022
| Name | Title | Pay | Year Born |
| Eric E. Easom | Co-Founder, Chief Executive Officer, President & Chairman of the Board | 860,297 | 1968 |
| Joseph S. Zakrzewski | Co-Founder & Independent Chairman of the Board | 64,577 | 1962 |
| Josh Eizen | Chief Legal Officer, Chief Operating Officer & Corporate Secretary | 565,988 | 1978 |
| Lucy O. Day | Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer | 588,860 | 1959 |
| George Harrison Talbot | Co-Founder & Senior Clinical Advisor | 0 | 1948 |
| Michael R. K. Alley | Co-Founder, Senior Vice President of Research Fellow & Head of Biology | 0 | N/A |
| Sanjay Chanda | Chief Development Officer | 0 | 1966 |
| Stephen David Prior | Chief Strategy Officer | 0 | 1958 |
| Vince Hernandez | Senior Vice President of Research & Head of Chemistry | 0 | N/A |
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.